EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSOTSG00005005578
Gene Symbol: LOC112266353
2 Cross references
212 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSOTSG00005007425
Gene Symbol: LOC112253654
2 Cross references
145 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSOTSG00005007964
Gene Symbol: LOC112226568
3 Cross references
199 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSOTSG00005043470
Gene Symbol: LOC112228636
3 Cross references
197 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSOTSG00005047865
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSOTSG00005001033
Gene Symbol: SLC18A2
1 Cross references
217 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSOTSG00005013064
Gene Symbol: SLC18A2
1 Cross references
217 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSOTSG00005004734
Gene Symbol: SLC29A1
1 Cross references
200 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSOTSG00005046383
Gene Symbol: SLC29A1
1 Cross references
203 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSOTSG00005033892
Gene Symbol: SLC5A1
1 Cross references
244 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSOTSG00005024639
Gene Symbol: SLC5A2
1 Cross references
192 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSOTSG00005046959
Gene Symbol: SLC5A2
1 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).